The U.S. Food and Drug Administration accepted Indivior PLC's application for RBP-7000, an investigational treatment for schizophrenia.
Schizophrenia is a chronic disorder characterized by a lifelong pattern of acute psychotic episodes superimposed upon chronically poor psychosocial adjustment.
The FDA is expected to approve the drug by July 28, 2018.
